Ipsilateral access portal venous embolization (PVE) for preoperative hypertrophy exhibits low complication rates in Clavien-Dindo and CIRSE scales

Roland Brüning 1,2*, Martin Schneider 1, Michel Tiede 1, Peter Wohlmuth 3, Gregor Stavrou 4, Thomas von Hahn 5,6, Andrea Ehrenfeld 5, Tim Reese 6,7, Georgios Makridis 7, Axel Stang 6,8 and Karl J. Oldhafer 6,7

Abstract

Background: Portal venous embolization (PVE) is a minimal invasive preoperative strategy that aims to increase future liver remnant (FLR) in order to facilitate extended hemihepatectomy. We analyzed our data retrospectively regarding complications and degree of hypertrophy (DH).

Methods: 88 patients received PVE either by particles / coils (n = 77) or by glue / oil (n = 11), supported by 7 right hepatic vein embolizations (HVE) by coils or occluders. All complications were categorized by the Clavien- Dindo (CD) and the CIRSE classification.

Results: In 88 patients (median age 68 years) there was one intervention with a biliary leak and subsequent drainage (complication grade 3 CD, CIRSE 3), two with prolonged hospital stay (grade 2 CD, grade 3 CIRSE) and 13 complications grade 1 CD, but no complications of grade 4 or higher neither in Clavien- Dindo nor in CIRSE classification. The median relative increase in FLR was 47% (SD 35%). The mean pre-intervention standardized FLR rose from 23% (SD 10%) to a post-intervention standardized FLR of 32% (SD 12%). The degree of hypertrophy (DH) was 9,3% (SD 5,2%) and the kinetic growth rate (KGR) per week was 2,06 (SD 1,84).

Conclusion: PVE and, if necessary, additional sequential HVE were safe procedures with a low rate of complications and facilitated sufficient preoperative hypertrophy of the future liver remnant.

Keywords: Portal vein embolization, PVE, Portal vein occlusion, FLR, Hypertrophy

Background

Recent advances in hepatobiliary surgery and the possibility of safely removing larger portions of the liver have improved the proportion of potentially resectable tumors in malignant liver disease (Abulkhir et al. 2008). However, if the proportion of the anticipated liver volume that remains in situ after surgery (the future liver remnant (FLR)) is small, patients remain at risk for developing postoperative complications such as liver failure (Abulkhir et al. 2008; Azoulay et al. 2000). The FLR is measured before planning surgery, as its volume has been shown to be a predictor for postoperative liver dysfunction (Shoup et al. 2003; Ribero et al. 2007). If necessary, a small FLR can be enlarged by hypertrophy strategies. The two most established methods are Associating Liver Partition with Portal vein ligation for Staged hepatectomy (ALPPS) (Schnitzbauer et al. 2012) and Portal Venous Embolization (PVE) (Makuuchi et al. 1990; de Baere et al. 1993; Abdalla et al. 2002), both of which are techniques to redirect portal blood flow, in an attempt to promote hypertrophy of.
nonembolized /nontreated segments that will remain after resection (Madoff et al. 2016).

The initial reports of the percutaneous approach to portal vein branches occlusion date were initiated, when Takayasu et al. reported on contralateral growth following ipsilateral (tumor) obstruction (Takayasu et al. 1986) and Kinoshita et al. (Kinoshita et al. 1985) reported on the transcutaneous transhepatic approach. Shortly after, animal studies exhibited the ability to regenerate (Tanaka et al. 1994) in a two-stage concept. Since then, PVE was developed and has gained relevant support worldwide (Luz et al. 2020).

An increased FLR volume once archived helps patients previously considered ineligible for resection (Abulkhir et al. 2008; Azoulay et al. 2000; Madoff et al. 2005). There is consensus that the necessary future liver volume is in the range of 25–40% and mainly depends on the quality of liver tissue (Abdalla et al. 2002; Benson 3rd et al. 2013; Kubota et al. 1997; Shirabe et al. 1999; de Meijer et al. 2010), and therefore on the underlying disease and histology.

From a technical standpoint, PVE can be varied substantially. We used two different embolization materials: Coils and particles versus glue and oil. An additional intervention using a different approach (hepatic vein embolization (HVE)) was employed in cases with a hypertrophy not sufficient for the next surgical step. In this retrospective evaluation, we sought to evaluate the degrees of hypertrophy, the kinetic growth of the future liver remnant and complications with respect to PVE procedures. Based on a preliminary analysis of our data, our hypothesis was that independent of materials used, PVE would allow a safe procedure with only few and low grade complications.

### Materials and methods

#### Patients

In a retrospective analysis of our hospital’s data base, a total of 114 interventions were identified between 2013 and 2019.

Inclusion criteria were primary or secondary liver lesions planned for extended right hemihepatectomy (ERH). Disease had to be liver dominant, and a tumor board vote had to be positive towards a hypertrophy model and hemihepatectomy. Pre- and postinterventional CT scans, laboratory parameters and biometric data needed to be available to be included. Ninety-five interventions in 88 patients were analyzed. The following patients were excluded from further analysis: 15 patients were lost to follow up or had insufficient scan quality, in 2 patients the retrospective data of the intervention / lab data were incomplete, and in another 2 patients there was an atypical (left) approach.

Ninety-five interventions in 88 patients were included and further analyzed: 88 PVE were evaluated and 7 HVE interventions were used. The patients and their hypertrophy data were also grouped by the underlying disease, please refer to Table 1 for further patient details.

#### Intervention

PVE was performed under general anesthesia by an experienced interventionalist (> 10 years of interventional radiology) and we used an ipsilateral approach to prevent damage to the FLR. The ultrasound-guided transcutaneous transhepatic approach with a dedicated puncture device (Toshiba Aplio XV; Toshiba Europe GmbH, Neuss, Germany) was performed in cooperation with an experienced sonographer in order to minimize punctation events. Following successful puncture of a

| Table 1 Patient data |
|----------------------|
| **Mean** | **SD** |
| **Total patients included** | 88 |
| Age (years; at the time of procedure) (lower quartile, median, upper quartile) | 59/68/74 | 11 |
| Gender male | 60 |
| Weight (kg) | 77 | 16 |
| Height (cm) | 173,4 | 7,7 |
| BMI (lower quartile, median, upper quartile) | 24,7/27,5/31,1 |
| BSA (Mosteller) (m2) | 1,90 | 0,27 |
| TELV (cm2) | 1635 | 269 |
| **Material and methods used** |
| PVE with Coils/PVA | 77 |
| PVE with Glue/Lipiodol | 11 |
| HVE with coils/occluder$^b$ | 7 |
| **Malignancies** |
| Colorectal liver metastasis (CRLM)$^a$ | 43 |
| Central bile duct/ Cholangiocellular carcinoma (CCC)$^a$ | 27 |
| Hepatocellular carcinoma$^c$ | 8 |
| Other$^c$ | 10 |

$^a$Inclusion criteria were primary or secondary liver lesions planned for extended right hemihepatectomy (ERH). Disease had to be liver dominant, and a tumor board vote had to be positive towards a hypertrophy model and hemihepatectomy. Pre- and postinterventional CT scans, laboratory parameters and biometric data needed to be available to be included. Ninety-five interventions in 88 patients were analyzed. The following patients were excluded from further analysis: 15 patients were lost to follow up or had insufficient scan quality, in 2 patients the retrospective data of the intervention / lab data were incomplete, and in another 2 patients there was an atypical (left) approach. One HVE was performed within the same session as PVE.

$^b$Of the patients with CRLM, 25 had previous surgery (as did all CRLM HVE patients), 3 had radiofrequency ablation (RFA), and 6 patients received FOLFOX or Bevacicumab (Avastin$^e$).

$^c$Of the patients with central bile duct tumors (intrahepatic CCC and or perihilar cholangiocarcinomas (Klatskin$^e$)), 5 had prior surgery and 5 had other previous interventions (such as ERCP or PTCD) - in total there were 9 pre-treated patients in this group.

$^d$Of the patients with central bile duct tumors (intrahepatic CCC and or perihilar cholangiocarcinomas (Klatskin)), 5 had prior surgery and 5 had other previous interventions (such as ERCP or PTCD) - in total there were 9 pre-treated patients in this group.

$^e$Regarding the patients with HCC, one patient had a previous trans-arterial chemoembolization and none had previous surgery.

$^f$Regarding the patients with other malignancies, 3 had previous surgery, 3 and 2 had other pretreatments (Y90 and RFA).
and KGR were calculated, as described by Shindoh et al. (2013) in order to assess both hypertrophy at the time of control and the dynamic development.

In selected cases HVE was added as a second procedure after interdisciplinary case discussion, when left lobe hypertrophy after PVE was insufficient for surgery (sFLR below 30). In total seven HVE were performed, of those were 6 in the described subsequent second step; the 7th HVE was performed at the discretion if the intervention-alist in a PVE session in a 57 year old female with CRLM: two hepatic vein occluders assisted the portal embolization, as the coil and particle based PVE technically seemed not sufficient.

Statistical methods
Continuous data were summarized as means +/- standard deviations or as medians [25th and 75th percentiles] as appropriate. Categorical data were presented as N (%). Outcome data (FLR, KGR) were shown by follow up time and intervention methods using scatterplots and a smoothed local regression curve. Response and histology were presented with boxplots. All calculations were performed with the statistical analysis software R.

Results
In the entire group hypertrophy of Segments 2 and 3 reached a median relative increase was 47% (SD 35%). The mean pre-intervention sFLR rose from 23% (SD 10%) to a post-intervention sFLR of 32% (SD 12%). The DH was 9,3% (SD 5,2%); and the KGR was 2,06 (SD 0,26).

Details of the effectiveness and grade of hypertrophy of FLR by the different embolization methods over time are given in Fig. 1a and details of the KGR are given in Fig. 1b.

The subgroup analysis of effectiveness and grade of hypertrophy of FLR by histology is displayed in Fig. 2a and b. To visualize the differences between the relative growth of group of malignancy, these results are given in Box-plots in Fig. 2c and d.

The following complications occurred: There was one PVE intervention necessitating subsequent drainage and revision of the central stents in a 52 year old female suffering from central bile duct tumor with a subsequent bilioma which had to be addressed by CT-guided drainage (Clavien- Dindo grade 3, CIRSE grade 3), however with sufficient hypertrophy and extended right hemihepatectomy to follow. Another PVE intervention had prolonged intermediate care in a 72 year old female a central portal vein stasis despite injection of 5000 IE heparin, this finding however was not reproduced in subsequent US and CT scans, so another PVE session completed the procedure (Clavien- Dindo grade 2; CIRSE 3), and the third
CIRSE 3 complication was a 69 year old female with self limiting hematemesis. There were 11 minor complications Grade 1 Clavien- Dindo. Of those interventions with a complication Clavien- Dindo grade 1–3, seven (54%) received treatment before PVE such as radiofrequency ablation. Two of those interventions (15%) were performed using glue and the others using coils/PVA, reflecting almost a normal distribution in our cohort. During four treatments displaced mReye coils were subsequently retrieved in the same session by a Snare® device (GooseNeck® Snare Kit; Covidien eV3, Plymouth, MN) (CIRSE grade1). Hospital stay was prolonged < 48 h in 6 patients (CIRSE grade 2).
and > 48 h in 3 patients (CIRSE grade 3). For further details please refer to Table 2.

PVE were followed by ERH in 61/88 patients (69%) across subgroups. In 6 cases, to enable more profound hypertrophy, HVE was added as a second procedure after interdisciplinary case discussion. In all 6 cases the left lobe hypertrophy after PVE was insufficient for surgery (mean sFLR 26.6). After PVE and additional HVE 4 out of 6 patients showed hypertrophy results that enabled them to receive the aimed hemihepatectomy.

Discussion
The most striking finding in our analysis was the low number of severe complications – those exceeding Clavien-Dindo grade 1 were about 2.2% and none exceeding grade 3. We assume that the right-sided approach under expert ultrasound guidance and the careful use of the embolization material could have contributed to this low complication rate: it has the benefit of avoiding damage to the FLR at the cost of more difficult navigation using reverse angle catheters, as described by Madoff et al. (Madoff et al. 2016).

Among the available scores, we selected to grade according to the most established (and published) Clavien-Dindo classification, however, this classification is intended for major surgery, and the CIRSE scale for interventions (Filippiadis et al. 2017). Other more aggressive embolization materials exhibited high growth rates, but PVE with N-butyl cyanoacrylate exhibited major complications in 19 patients (3.13%), while minor complications occurred in 38 patients (6.26%) (Wajswol et al. 2018). The use of ethanol-based PVE exhibited 9 major complications out of 151 (6%) PVE sessions and minor complications such as fever in 47 of 151 (31.1%) of procedures (Sakuhara et al. 2012). Morbidity has also been reported in two elderly patients with Klatskin tumors following PVE with gel-foam and coils and subsequent sepsis (Lee et al. 2017). Using the combined approach of HVE/PVE in the small group of 10 patients, two grade 3 and one grade 3 Clavien-Dindo complications have been reported (30%) (Guiu et al. 2017). Conversely, classic PVE-related
complications exceeding CD grade 2 were found in only 0.6% of the 494 patients of a Japanese series (Ebata et al. 2012). Summing up all different approaches, an early meta-analysis of Abulkir et al. reported a historical overall morbidity for PVE of 2.2% (Abulkir et al. 2008).

The low number of complications in our series with the endocasual and transcutaneous approach also compare favorably to the surgical technique of ALPPS, where complications leading to mortality are reported ranging from 4.2% to 29.1% of patients (Linecker et al. 2011; Wanis et al. 2021). Another group reported severe morbidity (Clavien-Dindo ≥3a) to occur in 50% (3/6) of the rescue ALPPS, 71% (10/14) of the ALPPS, and 38% (13/34) of the TSH/PVE patients ($p = 0.300$) (Narita et al. 2011). Consequently, for example Hahn et al., (Hahn et al. 2019) modified their surgical strategy and reported a Clavien-Dindo III-IV morbidity of 22% and mortality of 0%.

In our evaluation of hypertrophy following PVE we found a median relative increase of FLR of 47% across the entire group, which compares equally or favorably with previous publications, as various groups have previously reported a relative hypertrophy in a range of 30% - 50% (Wajswol et al. 2018; Geisel et al. 2014; van Lienden et al. 2013; Zeile et al. 2016).

Hypertrophy varies substantially between technical approaches: our subgroup analysis found the relative growth of FLR almost similar between coils and glue (44% and 43%, respectively). Conversely, there have been a publications indicating that glue yields a better result, as the utilization of N-butyl cyanoacrylate has been reported by Wajswol et al. to increase FLR by 49.4% ± 1.3% (Wajswol et al. 2018). Jaberi et al. reported a DH of 16.2% using glue vs 12.3% using PVA or combined with Amplatz (p < .009) (Jaberi et al. 2016). On the other hand, hypertrophy was described using PVA alone by Geisel et al. at 30.9% and in combination with coils at 53.3% (Geisel et al. 2014). However, differences between reported growth rates were huge and may have been a result of different patient selection and the presence or absence of con-current medication – limiting comparability. This situation with a huge span of DH was outlined in the recent review by Luz et al. (Luz et al. 2020). The review of van Lienden et.al., (van Lienden et al. 2013) calculated a mean DH to be 37.9%.

Trying to find a predictor for postsurgical failure we shared a special interest in KGR (defined as the degree of hypertrophy at initial postPVE volume assessment divided by number of weeks elapsed after PVE). It has been shown by Shindoh et al. (Shindoh et al. 2013), that the volumetric sFLR threshold for safe resection of 30% was not significantly associated with static hypertrophy. As a consequence, the same group presented the kinetic growth rate to be the more accurate predictor for post-surgical failure since the kinetic growth rate (KGR) has been suggested to better reflect the regenerative ability of the liver in patients undergoing PVE as it takes into account the duration necessary to achieve an adequate volume Liver kinetic growth rate predicts postsoperative liver failure after ALPPS (Kambakamba et al. 2016).

The KGR we found in our glue group was 2.6% per week and in the coils group 2.04% per week. A KGR of 3.5% per week in the glue group and 2.6% per week in the PVA group were reported by Jaberi (Jaberi et al. 2016). However, Guiu et al. reported in a smaller cohort a very high kinetic growth rate of 53% in 7 days following their combined PVE and HVE approach (Guiu et al. 2017), however, at the cost of increased sequelae as shown above.

To date, important factors affecting hypertrophy remain uncertain and may be based on patient selection, to various methods of embolization and so on. A previous analysis of cofactors outlined negative predictive factors such as the formation of porto-portal collaterals ($p = 0.004$) (Geisel et al. 2014).

### Table 2: Complications of PVE scored by the Clavien-Dindo score and the CIRSE score

| Complications Dindo-Clavien | Numbers (percentage) | Complications CIRSE grading | Numbers (percentage) |
|-----------------------------|----------------------|------------------------------|----------------------|
| Grade 1 (Any deviation from the normal postoperative course without the need for pharmacological treatment or surgical, endoscopic and radiological interventions) | 11/88 (12.5%) | Grade 1 (Complication during the procedure which could be solved within the same session; no additional therapy, no postprocedure sequelae, ...) | 4/88 (4.5%) |
| Grade 2 (Requiring pharmacological treatment with drugs other than such allowed for grade I complications) | 1/88 (1.1%) | Grade 2 (Prolonged observation including overnight stay (as a deviation from the normal post-therapeutic course 48 h) | 6/88 (6.8%) |
| Grade 3 (Requiring surgical, endoscopic or radiological intervention) | 1/88 (1.1%) | Grade 3 (Additional postprocedure therapy or prolonged hospital stay (48 h) required; no postprocedure sequelae) | 3/88 (3.4%) |
| Grade 4 (Life-threatening complication (including CNS complications)* requiring IC/ICU-management) | 0 (0%) | Grade 4 (Complication causing a permanent mild sequelae (resuming work and independent living)) | 0 (0%) |
| Grade 5 (death) | 0 (0%) | Grade 5 (Complication causing a permanent severe sequelae (requiring ongoing assistance in daily life)) | 0 (0%) |

* *
Regarding the effectiveness of hypertrophy between histological groups in the subgroup of colorectal liver metastasis (CRLM) we found a median relative growth of the FLR of 37%. However, there was a remarkable range of growth with a standard deviation of 43%, which we assume to be linked to the frequent pre-treatment in this group. The effects of pretreatment have been reported previously, although the effect of chemotherapy is not clear (Madoff et al. 2016). Zorzi et al. (Zorzi et al. 2008) reviewed FLR hypertrophy after PVE in patients with CRLM and showed comparable degrees of hypertrophy of treated patients when compared with the no chemotherapy group 4 weeks after PVE. However, in a small series of 15 consecutive patients by Beal et al. (Beal et al. 2006) the increase in FLR volume was reduced in the setting of chemotherapy (p < .016).

In the group of central bile duct tumors there was a median relative growth of the FLR of 37% (SD 18%). Nine of 27 patients received pre-treatment, of those, drainage of dilated bile ducts (n = 5). A DH of more than 20% has been reported in the large cohort of Nagino et al. (Nagino et al. 2006) to a pre-operative FLR of 460 cm³ by Ebata (Ebata et al. 2012).

In the HCC group we found a relative growth of the FLR of 58% (SD 37%). This DH exceeds the average result of 31% increase after PVE as reported in the recent review of Tustumi and coworkers (Tustumi et al. 2018). Interestingly, we did not observe a lack of growth by either cirrhosis or hepatic steatosis, typically preceding the development of HCC. This is in accordance with the report of Deipolyi et al. (Deipolyi et al. 2017) who did not observe neither effect in their subgroup.

The PVE based hypertrophy concept in our own group resulted in a rate of curative intended surgery of 69%. Intra- or extrahepatic disease progression in the interval was the main reason to preclude these approaches. Another reason was general medical deterioration, as was previously mentioned by Deipolyi (Deipolyi et al. 2017). The meta-analysis of van Lienden et al. (van Lienden et al. 2013) has outlined 6.1% local intrahepatic tumor progression in the FLR; and 8.1% extrahepatic tumor spread. Wajs wol et al. (Wajs wol et al. 2018) reported that 76% of PVE candidates underwent surgical resection. A 20% drop-out rate after first stage resection from disease progression was reported in another two-stage hepatectomy series (Narita et al. 2011; Hahn et al. 2019).

In central bile duct tumors, a 25% rate of non-resectability has been reported in a larger series by Ebata et al. (Ebata et al. 2012).

If growth of the FLR did not match the anticipated values, six patients underwent a subsequent session addressed by a right hepatic vein embolization (HVE). Following this sequential HVE, 4 of these patients could then receive major surgery. A combination of PVE and HVE in the same session was reported by Le Roy and coworkers with a DH of 52.6% (Le Roy et al. 2017). Guiu et al. (Guiu et al. 2017) found the FLR increased by 64.3% in a similar combined approach at day 21. On the other hand, Hwang et al. (Hwang et al. 2015) reported 42 patients to have a documented DH of FLR of 28.9% after sequential PVE-HVE.

Limitations of our study included that our data were analyzed in a retrospective fashion and were single centered including a learning curve, so there will be limitations on their impact. There was no uniformity in embolization technique and there was heterogeneity of the underlying liver tumors. However, there are no multicenter prospective studies either comparing FLR hypertrophy between ALPPS and PVE or regarding different embolization materials. Our evaluation did not include local functional capacity measurable e.g. by SPECT (not possible in our center). The measurement of indocyanine retention ratios were not available at that time and thus was not part of our analysis.

In conclusion PVE were safe procedures with a low rate of complications that allows preoperative hypertrophy and kinetic growth of the future liver remnant.

Abbreviations
FLR: Future liver remnant; DH: Degree of hypertrophy (=sFLR after PVE – sFLR before PVE); FLR/BWR: Future liver remnant to body weight ratio; HVE: Hepatic vein embolization; PVE: Portal vein embolization; sFLR: Future liver remnant standardized to the BMI by Mosteller, according to the formula sFLR = FLR/cm³/TELV/cm³*100; BMI: Body mass index; KGR: Kinetic growth rate defined as the degree of hypertrophy at initial postPVE volume assessment divided by number of weeks elapsed after PVE, according to the formula KGR = degree of hypertrophy/weeks; PVA: Polyvinyl alcohol particles; HCC: Hepatocellular carcinoma; CRLM: Colorectal liver metastasis; SD: Standard deviation; TELV: Total estimated liver volume, according to the formula, according to the formula TELV (cm³) = –794.41 + 1267.28 * BSA; ERH: Extended right hemihepatectomy; ALPPS: Associating Liver Partition with Portal vein ligation for Staged hepatectomy; CD: Clavien-Dindo classification; CIRSE classification of complications; Classification of complications

Acknowledgements
We acknowledge the input of Dr. Martin Zeille, Dr. Hannah Hentschel, Dr. Jana Tesdorff and Dr. Jan Eden Volkmer for patient handling, and Dr. Martin Zeille for establishing the BSA based sFLR calculation in our center. We strongly appreciate the input of Gabriela Ramlow and Anke Anstadt for the indispensable local data searches.

Authors’ contributions
Conceptualization: Roland Brüning, Karl Oldhafer. Methodology: Martin Schneider, Peter Wohlmuth, Andrea Ehrenfeld. Formal analysis and investigation: Martin Schneider, Peter Wohlmuth, Michel Tiede. Writing - original draft preparation: Roland Brüning, Martin Schneider, Michel Tiede. Writing - review and editing: Gregor Stavrou, Thomas von Hahn, Tim Reese, Georgios Makridis. Funding acquisition: Axel Stang, Karl Oldhafer. Resources: Supervision: Axel Stang, Karl Oldhafer. The authors read and approved the final manuscript.

Funding
The authors declare that they did not receive external funding.
Nagino M, Kamiyia J, Nishio H, Ebata T, Arai T, Nimura Y (2006) Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer: surgical outcome and long-term follow-up. Ann Surg 243(3):364–372. https://doi.org/10.1097/01.sla.0000201482.11876.14

Nanta M, Oussoultzoglou E, Jaeck D, Fuchschieler P, Rosso E, Persaux P, Marzano E, Bacheller P (2011) Two-stage hepatectomy for multiple bilobar colorectal liver metastases. Br J Surg 98(10):1463–1475. https://doi.org/10.1002/bjs.7580

Ribero D, Abdalla EK, Madoff DC, Donadon M, Loyer EM, Vauthey JN (2007) Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br J Surg 94(11):1386–1394. https://doi.org/10.1016/j.bjsurg.2007.04.009

Sakuhara Y, Abdo D, Hasegawa Y, Shimizu T, Kamiyama T, Hitoso S, Fukumori D, Kawamura T, Ito YM, Tha KK, Shisato H, Terae S (2012) Preoperative percutaneous transhepatic portal vein embolization with ethanol injection. AJR Am J Roentgenol 198(4):914–922. https://doi.org/10.2214/AJR.11.6515

Schnitzbauer AA, Lang SA, Goessmann H, Nadalin S, Baumgart J, Farkas SA, Fichtner-Feigl S, Loef T, Goracyk A, Hörbelt R, Kroemer A, Loss M, Rümmele P, Scherer MN, Padberg W, Königshainer A, Lang H, Obed A, Schlitt HJ (2012) Right portal vein ligation combined with in situ splitting induces rapid left lateral liver lobe hypertrophy enabling 2-staged extended right hepatic resection in small-for-size settings. Ann Surg 255(3):405–414. https://doi.org/10.1097/SLA.0b013e31824856f5

Shindoh J, Truty MJ, Alosa TA, Curley SA, Zimmetti G, Huang SY, Mahvash A, Gupta S, Wallace MJ, Vauthey JN (2013) Kinetic growth rate after portal vein embolization predicts posthepatectomy outcomes: toward zero liver-related mortality in patients with colorectal liver metastases and small future liver remnant. J Am Coll Surg 216(2):201–209. https://doi.org/10.1016/j.jamcollsurg.2012.10.018

Shibai K, Shimada M, Gion T, Hasegawa H, Takenaka K, Utsunomiya T, Sugimachi K (1999) Postoperative liver failure after major hepatic resection for hepatocellular carcinoma in the modern era with special reference to remnant liver volume. J Am Coll Surg 189(3):304–309. https://doi.org/10.1016/S1072-7515(99)00031-9

Shoup M, Gonen M, D’Angelica M, Jarnagin WR, DeMatteo R, Schwartz LH, Tuorto S, Blumgart LH, Fong Y (2003) Volumetric analysis predicts hepatic dysfunction in patients undergoing major liver resection. J Gastrointest Surg 7(3):325–330. https://doi.org/10.1016/S1091-255X(02)00370-0

Takayasu K, Muramatsu Y, Shima Y, Moriyama N, Yamada T, Makuchi M (1986) Hepatic lobar atrophy following obstruction of the ipsilateral portal vein from hilar cholangiocarcinoma. Radiology 160(2):389–393. https://doi.org/10.1148/radiology.1602.3014598

Tanaka H, Kinoshita H, Hirohashi K, Kubo S, Lee KC (1994) Increased safety by two-stage hepatectomy with preoperative portal vein embolization in rats. J Surg Res 57(6):687–692. https://doi.org/10.1006/jsre.1994.1202

Tustumi F, Ernani L, Coelho FF, Bernardo WM, Junior SS, Kruger JAP, Fonseca GM, Tanaka H, Kinoshita H, Hirohashi K, Kubo S, Lee KC (2016) Identification of cofactors influencing hypertrophy of the future liver remnant after portal vein embolization—the effect of collaterals on embolized liver volume. Br J Radiol 89(1068):20160306. https://doi.org/10.1246/bjrn.2016.0306

Zorzi D, Chun YS, Madoff DC, Abdalla EK, Vauthey JN (2008) Chemotherapy with bevacizumab does not affect liver regeneration after portal vein embolization in the treatment of colorectal liver metastases. Ann Surg Oncol 15(10):2765–2772. https://doi.org/10.1245/s10434-008-0035-7

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.